Parimifasor
Parimifasor (LYC-30937-EC, LYC30937) is an orally bioavailable, enteric-coated ATPase modulator as a gut-directed therapy for the treatment of inflammatory bowel disease (IBD) .Psoriasis Phase 2 Clinical.
Product Specifications
CAS Number
1796641-10-5
Product Name Alternative
LYC-30937-EC | LYC30937
Purity
>98% (HPLC)
Solubility
DMSO: ≥150 mg/mL (< 1 mg/ml refers to the product slightly soluble or insoluble)
Smiles
O=C (/N=C (NC1=CC (F) =CC (Cl) =C1) \NC2=NNC (C (F) (F) F) =C2) C3=CC=CC (Cl) =C3
Molecular Formula
C18H11Cl2F4N5O
Molecular Weight
460.214
Storage Conditions
Storage temperature: -20°C. Stability: ≥ 2 years
Notes
For research use only.
Other Product Names
3-chloro-N-[ (3-chloro-5-fluoroanilino) {[5- (trifluoromethyl) -1H-pyrazol-3-yl]amino}methylidene]benzamide
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
GTR15115266 1 Vial
Lentiviral human COX7C shRNA (UAS) - Lentiviral human COX7C shRNA (UAS) (100)
Sign In for Pricing
View Details 